Glycation products as markers and predictors of the progression of diabetic complications

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 567-581

  Monnier, Vincent M ^a   Sell, David R ^a   Genuth, Saul ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Age; Diabetic complications; Glycation product

Indexed keywords

3 DEOXYGLUCOSONE; 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; METHYLGLYOXAL; PENTOSIDINE;

CHRONIC DISEASE; COMPARATIVE STUDY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE MARKER; GLUCOSE BLOOD LEVEL; GLYCATION; HEART VENTRICLE FAILURE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; JOINT STIFFNESS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OXIDATIVE STRESS; PROLIFERATIVE RETINOPATHY; QUANTITATIVE ANALYSIS; RETINA MACULA EDEMA; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SERUM; SKIN;

EID: 23744467295     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.065     Document Type: Conference Paper

References (78)

1. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 977-986.
2. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853.
3. MONNIER, V.M. & A. CERAMI. 1981. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. Science 211: 491-493.
4. MONNIER, V.M., R.R. KOHN & A. CERAMI. 1984. Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl. Acad. Sci. USA 81: 583-587.
5. MONNIER, V.M. et al. 1986. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N. Engl. J. Med. 314: 403-408.
6. MCCANCE, D.R. et al. 1993. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 91: 2470-2478.
7. BEISSWENGER, P.J. et al. 1993. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J. Clin. Invest. 92: 212-217.
8. BEISSWENGER, P.J. et al. 1995. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44: 824-829.
9. SELL, D.R. et al. 1992. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41: 1286-1292.
10. MONNIER, V.M. et al. 1999. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48: 870-880.
11. 1999. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22: 99-111.
12. SIVITZ, W.I. et al. 2004. Skin collagen glycation products predict the progression risk of diabetic retinopathy and nephropathy in the epidemiology of diabetes and intensive control study (EDIC). Diabetes 53: A58.
13. HENLE, T. & T. MIYATA. 2003. Advanced glycation end products in uremia. Adv. Ren. Replace. Ther. 10: 321-331.
14. VISHWANATH, V. et al. 1986. Glycation of skin collagen in type I diabetes mellitus. Correlation with long-term complications. Diabetes 35: 916-921.
15. MONNIER, V.M. 2003. Intervention against the Maillard reaction in vivo. Arch. Biochem. Biophys. 419: 1-15.
16. TANEDA, S. & V.M. MONNIER. 1994. ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clin. Chem. 40: 1766-1773.
17. ODETTI, P. et al. 1992. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 41: 153-159.
18. SHAW, J.N., J.W. BAYNES & S.R. THORPE. 2002. Nepsilon-(carboxymethyl) lysine (CML) as a biomarker of oxidative stress in long-lived tissue proteins. Methods Mol. Biol. 186: 129-137.
19. TEERLINK, T. et al. 2004. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin. Chem. 50: 1222-1228.
20. REDDY, S. et al. 1995. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10888.
21. BOEHM, B.O. et al. 2004. Elevated serum levels of N(epsilon)- carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 47: 1376-1379.
22. MELLINGHOFF, A.C. et al. 1997. Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosity. Diabet. Med. 14: 832-836.
23. SCHIEL, R. et al. 2004. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN). Eur. J. Med. Res. 9: 391-399.
24. TAKEUCHI, M. et al. 1999. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) ir serum of diabetic patients. Mol. Med. 5: 393-405.
25. FRIEDLANDER, M.A. et al. 1996. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis. J. Clin. Invest. 97: 728-735.
26. WEISS, M.F. et al. 2000. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int. 57: 2571-2585.
27. AGALOU, S. et al. 2003. Removal of advanced glycation end products in clinical renal failure by peritoneal dialysis and haemodialysis. Biochem. Soc. Trans. 31: 1394-1396.
28. SUGIYAMA, S. et al. 1998. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J. Am. Soc. Nephrol. 9: 1681-1688.
29. KITAUCHI, T. et al. 2004. Association between pentosidine and arteriosclerosis in patients receiving hemodialysis. Clin. Exp. Nephrol. 8: 48-53.
30. CHENG, R. et al. 2004. Structure elucidation of a novel yellow chromophore from human lens protein. J. Biol. Chem. 279: 45441-45449.
31. TESSIER, F., M. OBRENOVICH & V.M. MONNIER. 1999. Structure and mechanism of formation of human lens fluorophore LM-1. Relationship to vesperlysine A and the advanced Maillard reaction in aging, diabetes, and cataractogenesis. J. Biol. Chem. 274: 20796-20804.
32. THORNALLEY, P.J. et al. 2003. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J. 375: 581-592.
33. HAMMES, H.P. et al. 1999. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon- (carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 42: 603-607.
34. SATO, E. et al. 2001. Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy. Diabetes Care 24: 479-482.
35. KOEFOED THEIL, P. et al. 1996. Lens autofluorescence is increased in newly diagnosed patients with NIDDM. Diabetologia 39: 1524-1527.
36. KOBAYASHI, K. & H. IGIMI. 1996. Glycation index of hair for non-invasive estimation of diabetic control. Biol. Pharm. Bull. 19: 487-490.
37. LYONS, T.J. et al. 1991. Decrease in skin collagen glycation with improved glycemic control in patients with insulin-dependent diabetes mellitus. J. Clin. Invest. 87: 1910-1915.
38. VERZUL, N. et al. 2000. Effect of collagen turnover on the accumulation of advanced glycation endproducts. J. Biol. Chem. 275: 39027-39031.
39. CONTRERAS, I. et al. 1997. Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Diabetes Care 20: 832-835.
40. WEISS, M.F. et al. 1998. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group. Kidney Int. 54: 193-202.
41. SCHIEL, R. et al. 2003. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN). J. Diabetes Complications 17: 90-97.
42. MONNIER, V.M. et al. 2004. Skin collagen fluorescence predicts coronary artery calcium deposition in the epidemiology of diabetes intervention and complications (EDIC) study. Diabetes 53: A77.
43. HEIN, G. et al. 2003. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford) 42: 1242-1246.
44. MEERWALDT, R. et al. 2004. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47: 1324-1330.
45. SCHALKWIJK, C.G. et al. 1999. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 48: 2446-2453.
46. MIYATA, T. et al. 1998. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem. Biophys. Res. Commun. 244: 45-49.
47. ONO, Y. et al. 1998. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res. Clin. Pract. 41: 131-137.
48. CHIARELLI, F. et al. 1999. Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J. Pediatr. 134: 486-491.
49. CHIARELLI, F. et al. 2000. Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Pediatr. Nephrol. 14: 841-846.
50. BERG, T.J. et al. 1999. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22: 1186-1190.
51. KILHOVD, B.K. et al. 1999. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22: 1543-1548.
52. KIUCHI, K. et al. 2001. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85: 87-91.
53. ASO, Y. et al. 2000. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol. 37: 87-92.
54. TAN, K.C. et al. 2002. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 25: 1055-1059.
55. TURK, Z. et al. 2003. Products of advanced glycation in patients with type 2 diabetes and vascular disease. Ann. Clin. Biochem. 40: 552-559.
56. TAN, K.C. et al. 2004. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 27: 223-228.
57. GALLER, A. et al. 2003. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 26: 2609-2615.
58. ZILIN, S. et al. 2001. The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy. Clin. Chim. Acta 313: 69-75.
59. SHARP, P.S., S. RAINBOW & S. MUKHERJEE. 2003. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet. Med. 20: 575-579.
60. THOMAS, M.C. et al. 2004. Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. Kidney Int. 66: 1167-1172.
61. KALOUSOVA, M. et al. 2004. Advanced glycation end-products in patients with chronic alcohol misuse. Alcohol Alcohol. 39: 316-320.
62. BERG, T.J. et al. 1998. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 21: 1997-2002.
63. ENDO, M. et al. 2001. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Horm. Metab. Res. 33: 317-322.
64. WAGNER, Z. et al. 2001. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. Am. J. Kidney Dis. 38: 785-791.
65. MIURA, J. et al. 2003. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J. Diabetes Complications 17: 16-21.
66. WAUTIER, M.P. et al. 2003. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab. 29: 44-52.
67. LIEUW, A.F.M.L. et al. 2004. Increased levels of N(epsilon)- (carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Nephrol. Dial. Transplant. 19: 631-636.
68. UCHIMURA, T. et al. 2001. Elevation of N-(carboxymethyl)valine residue in hemoglobin of diabetic patients. Its role in the development of diabetic nephropathy. Diabetes Care 24: 891-896.
69. KILHOVD, B.K. et al. 2003. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 52: 163-167.
70. YEGIN, A. & T. OZBEN. 1995. Serum glycated lipoproteins in type II diabetic patients with and without complications. Ann. Clin. Biochem. 32: 459-463.
71. AOKI, S. et al. 2000. Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy. Diabetes Res. Clin. Pract. 48: 119-125.
72. NICOLOFF, G. et al. 2002. Antibodies to advanced glycation end products in children with diabetes mellitus. Vascul. Pharmacol. 39: 39-45.
73. YAMAGUCHI, M. et al. 1998. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy. Diabet. Med. 15: 458-462.
74. SCHRAM, M.T. et al. 2003. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 26: 2165-2173.
75. CHEN, J.R. et al. 1999. Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 38: 1275-1278.
76. BEISSWENGER, P.J., L.L. MOORE & T.J. CURPHEY. 1993. Relationship between glycemic control and collagen-linked advanced glycosylation end products in type I diabetes. Diabetes Care 16: 689-694.
77. NAKAMURA, N. et al. 2003. Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes. In Vivo 17: 177-180.
78. KESSEL, L. et al. 2004. Lens fluorescence and metabolic control in type 1 diabetic patients: a 14 year follow up study. Br. J. Ophthalmol. 88: 1169-1172.